Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$14.09 +0.6%	$14.30	$10.57 ▼ $33.33	$2.05B	1.32	1.13 million shs	1.01 million shs
MIRM Mirum Pharmaceuticals	$50.80 +0.2%	$44.09	$28.56 ▼ $54.23	$2.52B	0.95	493,818 shs	414,089 shs
SDGR Schrodinger	$21.05 +0.8%	$23.80	$16.60 ▼ $28.47	$1.54B	1.63	903,537 shs	1.17 million shs
TRUU True Drinks	$0.10 +17.8%	$0.10	$0.00 ▼ $0.08	$494.78M	10.9	1.01 million shs	303,316 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	0.00%	-5.63%	-1.40%	-2.36%	-31.67%
MIRM Mirum Pharmaceuticals	0.00%	+3.63%	+12.04%	+8.04%	+73.68%
SDGR Schrodinger	0.00%	-7.80%	-2.23%	-3.44%	+8.95%
TRUU True Drinks	-7.01%	-7.87%	+17.06%	+126.65%	-33.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.366 of 5 stars	4.5	1.0	0.0	4.7	2.5	2.5	0.0
MIRM Mirum Pharmaceuticals	3.724 of 5 stars	3.6	1.0	0.0	4.2	2.4	0.8	0.6
SDGR Schrodinger	2.5128 of 5 stars	3.5	1.0	0.0	0.0	3.0	2.5	0.6
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	139.28% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	28.94% Upside
SDGR Schrodinger	3.00	Buy	$32.80	55.82% Upside
TRUU True Drinks	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRUU, MIRM, DNLI, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/16/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.19	N/A	N/A	$8.53 per share	1.65
MIRM Mirum Pharmaceuticals	$336.89M	7.47	N/A	N/A	$4.70 per share	10.81
SDGR Schrodinger	$207.54M	7.44	N/A	N/A	$5.78 per share	3.64
TRUU True Drinks	$1.95M	253.74	N/A	N/A	($0.03) per share	-3.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
TRUU True Drinks	-$3.88M	$0.01	9.95	∞	N/A	-255.80%	N/A	-165.86%	N/A

Latest TRUU, MIRM, DNLI, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.56	9.56
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
SDGR Schrodinger	N/A	3.45	3.45
TRUU True Drinks	N/A	0.01	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
MIRM Mirum Pharmaceuticals	N/A
SDGR Schrodinger	79.05%
TRUU True Drinks	N/A

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
MIRM Mirum Pharmaceuticals	14.36%
SDGR Schrodinger	8.60%
TRUU True Drinks	18.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
TRUU True Drinks	40	4.97 billion	N/A	Not Optionable

TRUU, MIRM, DNLI, and SDGR Headlines

Recent News About These Companies

True Drinks (OTCMKTS:TRUU) Stock Crosses Above Fifty Day Moving Average - Here's Why

June 1, 2025 | marketbeat.com

Beer News: True Acts Of Aletruism / New “Indie Beer” Campaign

November 13, 2024 | americancraftbeer.com

How Much Alcohol Can You Drink a Week and Still Be Healthy?

November 13, 2024 | msn.com

Starbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional facts

November 9, 2024 | msn.com

Can You Drink Alcohol After Getting a COVID-19 Booster?

October 29, 2024 | health.com

It's True: Some Pizza Hut Locations Still Serve Alcohol

October 22, 2024 | yahoo.com

Review: True Story Finished Bourbon

October 21, 2024 | msn.com

Vitalizes Body and Mind.®

October 4, 2024 | redbull.com

7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’

October 2, 2024 | msn.com

‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in it

September 21, 2024 | nypost.com

Seattle’s True Loves Drop a Funky New Single

August 31, 2024 | msn.com

Cannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinks

August 31, 2024 | msn.com

These alcoholic drinks can raise the risk of gout, a painful type of arthritis

August 30, 2024 | nypost.com

14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master Mixologist

August 29, 2024 | yahoo.com

7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)

August 25, 2024 | bbc.co.uk

12 Unhealthiest Drinks You Should Think Twice About Ordering At A Bar

August 18, 2024 | msn.com

True Loaf Bakery gets starter from two local bakers

August 10, 2024 | msn.com

PD TRUE : STREAM IT OR SKIP IT?

August 6, 2024 | decider.com

10 Drinks People Fake Liking to Fit In

August 5, 2024 | msn.com

16 Best Summer Cocktails for a Hot Weather Buzz

July 26, 2024 | esquire.com

What is ‘fluffy Coke’? Sugary drink dubbed ‘diabetes in a cup’ is the hottest beverage of the summer

July 23, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRUU, MIRM, DNLI, and SDGR Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$14.09 +0.08 (+0.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$14.08 -0.01 (-0.07%)

As of 06/18/2025 04:40 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$50.80 +0.10 (+0.20%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$50.77 -0.03 (-0.06%)

As of 06/18/2025 05:52 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Schrodinger NASDAQ:SDGR

$21.05 +0.17 (+0.81%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$21.11 +0.06 (+0.29%)

As of 06/18/2025 07:55 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

True Drinks OTCMKTS:TRUU

$0.10 +0.02 (+17.75%)

As of 06/18/2025

True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time